Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Emerging Therapies

Nov 09 2025
Convention Center: Room 152, Level 1
12:30 PM - 2:00 PM

World Class Speakers

Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD
Industry Presenter

Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD

Liver Institute Northwest
Tara Kearns, MSW, LMSW
Industry Presenter

Tara Kearns, MSW, LMSW
Nisreen Soufi, MD
Industry Presenter

Nisreen Soufi, MD

Children Hospital Los Angeles, Keck School of Medicine, USC

Description

In this activity, experts in adult and paediatric hepatology and gastroenterology explore practical strategies and evidence-based tools to diagnose and facilitate tailored treatment decision-making for primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC). 

Supported by: Ipsen Biopharmaceuticals, Inc. 

Organized by: PeerVoice

CME Provider: USF Health 

Link: https://cme.peervoice.com/140202451_1/140202451_1_p1/stage1reg?CountryID=US&ProjectNumber=140202451_1

Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

Journey Maps

Objectives

  • Utilise practical approaches, including evidence-based tools, to evaluate and predict response to therapy and facilitate treatment decision-making in patients with cholestatic liver disease.
  • Appraise the data from trials and studies examining the safety and efficacy of therapies in primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC).
  • Implement evidence-based treatment strategies to optimise clinical and patient-related outcomes in the management of PBC and PFIC. Describe the clinical presentation and biochemical abnormalities in patients with PBC and PFIC.